What is TuHURA Biosciences's earnings per share (EPS)?

TuHURA Biosciences (HURA) reported diluted earnings per share of $-0.63 for fiscal year 2025. This represents a 47.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

TuHURA Biosciences Financials

HURA

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows TuHURA Biosciences (HURA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

TuHURA Biosciences passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.92x

For every $1 of reported earnings, TuHURA Biosciences generates $0.92 in operating cash flow (-$27.6M OCF vs -$30.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$30.1M

YoY-38.6%

TuHURA Biosciences reported -$30.1M in net income in fiscal year 2025. This represents a decrease of 38.6% from the prior year.

EPS (Diluted)

$-0.63

YoY+47.9%

TuHURA Biosciences earned $-0.63 per diluted share (EPS) in fiscal year 2025. This represents an increase of 47.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$27.7M

YoY-87.4%

TuHURA Biosciences generated -$27.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 87.4% from the prior year.

Cash & Debt

$3.6M

YoY-71.4%

5Y CAGR+8.6%

10Y CAGR+7.5%

TuHURA Biosciences held $3.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

64M

YoY+50.2%

TuHURA Biosciences had 64M shares outstanding in fiscal year 2025. This represents an increase of 50.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-143.6%

YoY+5.0pp

5Y CAGR+3326.4pp

TuHURA Biosciences's ROE was -143.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 5.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$20.5M

YoY+54.0%

5Y CAGR+41.4%

10Y CAGR+23.2%

TuHURA Biosciences invested $20.5M in research and development in fiscal year 2025. This represents an increase of 54.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$76K

YoY+31.4%

TuHURA Biosciences invested $76K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 31.4% from the prior year.

HURA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	$0	$0	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$20.5M+54.0%	$13.3M+41.8%	$9.4M-38.0%	$15.2M+28.4%	$11.8M+225.5%	$3.6M
SG&A Expenses	$7.6M+75.8%	$4.3M+4.1%	$4.1M-44.8%	$7.5M-23.0%	$9.8M+116.1%	$4.5M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$625K-84.9%	$4.1M+22044.2%	$19K	N/A	$30K	N/A
Income Tax	$2K-57.5%	$4K	$0	N/A	N/A	N/A
Net Income	-$30.1M-38.6%	-$21.7M+26.0%	-$29.3M-29.4%	-$22.7M+40.8%	-$38.3M-319.7%	-$9.1M
EPS (Diluted)	$-0.63+47.9%	$-1.21	$-2.47	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	$0	N/A	N/A	N/A	$0	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.0M+0.8%	$4.9M+7.5%	$4.6M	N/A	$2.9M+4.4%	$2.8M-21.3%	$3.6M+3133.3%	$111K
SG&A Expenses	$1.8M-64.4%	$4.9M+103.2%	$2.4M	N/A	$783K-1.5%	$796K-21.7%	$1.0M+12.0%	$908K
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$17K	N/A	N/A	N/A	$2.0M+47.5%	$1.4M+432.1%	$255K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$7.1M+25.4%	-$9.5M-42.9%	-$6.7M	N/A	-$5.6M-6.0%	-$5.3M-8.7%	-$4.8M-373.3%	-$1.0M
EPS (Diluted)	$-0.14+33.3%	$-0.21-40.0%	$-0.15	N/A	$-0.54-25.6%	$-0.43-7.5%	$-0.40	N/A

HURA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$27.4M+37.0%	$20.0M+357.8%	$4.4M-72.6%	$15.9M+17.8%	$13.5M+361.0%	$2.9M
Current Assets	$4.6M-76.4%	$19.6M+371.5%	$4.2M-68.6%	$13.3M+12.4%	$11.8M+313.6%	$2.9M
Cash & Equivalents	$3.6M-71.4%	$12.7M+245.3%	$3.7M-68.9%	$11.8M+11.8%	$10.5M+340.5%	$2.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$10.7M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.4M+19.5%	$5.4M-9.3%	$5.9M+42.6%	$4.2M+40.2%	$3.0M+10.7%	$2.7M
Current Liabilities	$5.9M+11.1%	$5.3M+48.2%	$3.6M-9.9%	$4.0M+43.5%	$2.8M+3.9%	$2.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$20.9M+43.4%	$14.6M+1036.3%	-$1.6M-113.2%	$11.8M+11.5%	$10.6M+3923.2%	$263K
Retained Earnings	-$141.2M-27.1%	-$111.1M-25.6%	-$88.5M+35.1%	-$136.4M-22.6%	-$111.2M-59.5%	-$69.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$25.7M-25.8%	$34.6M+136.5%	$14.6M-26.7%	$20.0M+382.3%	$4.1M-33.2%	$6.2M-16.7%	$7.4M+70.7%	$4.4M
Current Assets	$3.5M-72.1%	$12.5M-12.5%	$14.3M-27.0%	$19.6M+463.0%	$3.5M-37.0%	$5.5M-18.2%	$6.8M+62.4%	$4.2M
Cash & Equivalents	$2.7M-68.3%	$8.5M+36.9%	$6.2M-50.9%	$12.7M+319.1%	$3.0M-38.5%	$4.9M-22.7%	$6.4M+73.3%	$3.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$13.6M0.0%	$13.6M	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.9M-41.2%	$15.2M+217.3%	$4.8M-11.0%	$5.4M-22.2%	$6.9M-47.5%	$13.2M-2.6%	$13.5M+128.2%	$5.9M
Current Liabilities	$8.8M-41.8%	$15.2M+217.3%	$4.8M-10.3%	$5.3M+136.2%	$2.3M-0.1%	$2.3M+68.5%	$1.3M-62.7%	$3.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$16.8M-13.7%	$19.4M+97.3%	$9.9M-32.5%	$14.6M+627.4%	-$2.8M+60.2%	-$7.0M-14.7%	-$6.1M-289.2%	-$1.6M
Retained Earnings	-$134.4M-5.6%	-$127.3M-8.1%	-$117.8M-6.0%	-$111.1M+31.4%	-$162.1M-1.4%	-$159.9M-1.5%	-$157.6M-78.1%	-$88.5M

HURA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$27.6M-87.6%	-$14.7M-23.2%	-$12.0M+41.4%	-$20.4M-8.1%	-$18.9M-137.9%	-$7.9M
Capital Expenditures	$76K+31.4%	$58K-26.9%	$79K-56.0%	$180K	N/A	N/A
Free Cash Flow	-$27.7M-87.4%	-$14.8M-22.9%	-$12.0M+41.5%	-$20.6M	N/A	N/A
Investing Cash Flow	-$1.3M+77.9%	-$6.1M-366.7%	-$1.3M	N/A	$964K	N/A
Financing Cash Flow	$19.9M-33.1%	$29.8M+1019.2%	$2.7M-87.7%	$21.6M-16.9%	$26.0M+294.5%	$6.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$25K	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$11.1M-77.4%	-$6.2M-31.9%	-$4.7M-82.3%	-$2.6M-37.6%	-$1.9M+62.7%	-$5.1M-32.1%	-$3.8M-81.1%	-$2.1M
Capital Expenditures	$0-100.0%	$6K-87.0%	$43K+99.3%	$21K	$0	N/A	N/A	N/A
Free Cash Flow	-$11.1M-77.3%	-$6.3M-30.8%	-$4.8M-82.4%	-$2.6M-38.8%	-$1.9M	N/A	N/A	N/A
Investing Cash Flow	$0+100.0%	-$156K+86.4%	-$1.2M-39.8%	-$824K+84.1%	-$5.2M	N/A	$0	N/A
Financing Cash Flow	$5.3M-39.4%	$8.7M+1687.5%	-$548K+84.4%	-$3.5M-122.4%	$15.7M+21.3%	$13.0M+179.7%	$4.6M+79.6%	$2.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HURA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-143.6%+5.0pp	-148.6%	N/A	-192.1%+169.8pp	-361.9%+3108.0pp	-3470.0%
Return on Assets	-109.9%-1.3pp	-108.6%+563.5pp	-672.1%-530.0pp	-142.1%+140.7pp	-282.8%+27.8pp	-310.6%
Current Ratio	0.78-2.9	3.68+2.5	1.16-2.2	3.32-0.9	4.24+3.2	1.07
Debt-to-Equity	0.31-0.1	0.37+4.2	-3.80-4.2	0.35+0.1	0.28-9.9	10.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-42.3%+6.6pp	-49.0%+18.6pp	-67.6%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-27.6%-0.1pp	-27.5%+18.0pp	-45.5%	N/A	-134.8%-49.9pp	-84.9%-19.9pp	-65.0%-41.6pp	-23.4%
Current Ratio	0.40-0.4	0.83-2.2	3.00-0.7	3.68+2.1	1.54-0.9	2.45-2.6	5.04+3.9	1.16
Debt-to-Equity	0.53-0.2	0.78+0.3	0.49+0.1	0.37+2.9	-2.50-0.6	-1.89+0.3	-2.23+1.6	-3.80
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: The current ratio is below 1.0 (0.78), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Io Biotech, Inc. IOBT

$4.2M

Oncolytics Biotech Inc ONCY

$91.3M

Pyxis Oncology, Inc. PYXS

$91.7M

Avalo Therapeutics Inc AVTX

$340.2M

Skye Bioscience SKYE

$20.5M

Frequently Asked Questions

Is TuHURA Biosciences profitable?

No, TuHURA Biosciences (HURA) reported a net income of -$30.1M in fiscal year 2025.

What is TuHURA Biosciences's return on equity (ROE)?

TuHURA Biosciences (HURA) has a return on equity of -143.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is TuHURA Biosciences's free cash flow?

TuHURA Biosciences (HURA) generated -$27.7M in free cash flow during fiscal year 2025. This represents a -87.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is TuHURA Biosciences's operating cash flow?

TuHURA Biosciences (HURA) generated -$27.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are TuHURA Biosciences's total assets?

TuHURA Biosciences (HURA) had $27.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are TuHURA Biosciences's capital expenditures?

TuHURA Biosciences (HURA) invested $76K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does TuHURA Biosciences spend on research and development?

TuHURA Biosciences (HURA) invested $20.5M in research and development during fiscal year 2025.

How many shares does TuHURA Biosciences have outstanding?

TuHURA Biosciences (HURA) had 64M shares outstanding as of fiscal year 2025.

What is TuHURA Biosciences's current ratio?

TuHURA Biosciences (HURA) had a current ratio of 0.78 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is TuHURA Biosciences's debt-to-equity ratio?

TuHURA Biosciences (HURA) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is TuHURA Biosciences's return on assets (ROA)?

TuHURA Biosciences (HURA) had a return on assets of -109.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is TuHURA Biosciences's cash runway?

Based on fiscal year 2025 data, TuHURA Biosciences (HURA) had $3.6M in cash against an annual operating cash burn of $27.6M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is TuHURA Biosciences's Piotroski F-Score?

TuHURA Biosciences (HURA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are TuHURA Biosciences's earnings high quality?

TuHURA Biosciences (HURA) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.